RYSBEVI
Live / Allowed — Notice of allowance issued (as of 30 Dec 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 24 Jun 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99249858
- Mark type
- Stylized text
- Filed
- 24 Jun 2025
- Published for opposition
- 04 Nov 2025
- Attorney of record
- Maury M Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations containing viral vectors for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations for gene therapy, gene editing, and genome editing for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Gene therapies, in the nature of pharmaceutical preparations, for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 30 Dec 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Nov 2025 — PUBLISHED FOR OPPOSITION
- 29 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Sept 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 04 Sept 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 04 Sept 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 02 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 02 Sept 2025 — NON-FINAL ACTION E-MAILED
- 02 Sept 2025 — NON-FINAL ACTION WRITTEN
- 02 Sept 2025 — ASSIGNED TO EXAMINER
- 24 Jun 2025 — APPLICATION FILING RECEIPT MAILED
- 24 Jun 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 24 Jun 2025 — NEW APPLICATION ENTERED